

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Roche Bio Denmark A/S</td> <td>12/06/2006</td> </tr> </tbody> </table>		Name	Execution Date	Roche Bio Denmark A/S	12/06/2006						
Name	Execution Date										
Roche Bio Denmark A/S	12/06/2006										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>Borean Pharma ApS</td> </tr> <tr> <td>Street Address:</td> <td>Gustav Wieds Vej 10</td> </tr> <tr> <td>City:</td> <td>Aarhus C</td> </tr> <tr> <td>State/Country:</td> <td>DENMARK</td> </tr> <tr> <td>Postal Code:</td> <td>DK-8000</td> </tr> </table>		Name:	Borean Pharma ApS	Street Address:	Gustav Wieds Vej 10	City:	Aarhus C	State/Country:	DENMARK	Postal Code:	DK-8000
Name:	Borean Pharma ApS										
Street Address:	Gustav Wieds Vej 10										
City:	Aarhus C										
State/Country:	DENMARK										
Postal Code:	DK-8000										
<table border="1"> <tr> <td>Name:</td> <td>Hoffman-La Roche, Inc.</td> </tr> <tr> <td>Street Address:</td> <td>340 Kingsland Street</td> </tr> <tr> <td>City:</td> <td>Nutley</td> </tr> <tr> <td>State/Country:</td> <td>NEW JERSEY</td> </tr> <tr> <td>Postal Code:</td> <td>07110-1199</td> </tr> </table>		Name:	Hoffman-La Roche, Inc.	Street Address:	340 Kingsland Street	City:	Nutley	State/Country:	NEW JERSEY	Postal Code:	07110-1199
Name:	Hoffman-La Roche, Inc.										
Street Address:	340 Kingsland Street										
City:	Nutley										
State/Country:	NEW JERSEY										
Postal Code:	07110-1199										
PROPERTY NUMBERS Total: 2											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>12405003</td> </tr> <tr> <td>Application Number:</td> <td>12405021</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	12405003	Application Number:	12405021				
Property Type	Number										
Application Number:	12405003										
Application Number:	12405021										
CORRESPONDENCE DATA											
Fax Number:	(312)913-0002										
Phone:	3129130001										
Email:	docketing@mbhb.com										
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>											
Correspondent Name:	McDonnell Boehnen Hulbert & Berghoff LLP										
Address Line 1:	300 S. Wacker Dr.										
Address Line 4:	Chicago, ILLINOIS 60606										

CH \$80.00 12405003

ATTORNEY DOCKET NUMBER:	08-347-US-DIV, -CON2
NAME OF SUBMITTER:	Donald L. Zuhn, Jr.
Total Attachments: 4 source=2006-12-06_Assignment#page1.tif source=2006-12-06_Assignment#page2.tif source=2006-12-06_Assignment#page3.tif source=2006-12-06_Assignment#page4.tif	

U.S. ASSIGNMENT

WHEREAS, We

Roche Bio Denmark A/S
Gustav Wieds Vej 10
DK-8000 Aarhus C
Denmark,

a company organized and existing under the laws of The United Kingdom of Denmark, were formerly named,

Borean Pharma A/S
Gustav Wieds Vej 10
DK-8000 Aarhus C
Denmark;

and

WHEREAS, We, Roche Bio Denmark A/S, are submitting concurrently herewith for recording in the Assignment records of the United States Patent & Trademark Office a copy of the certification from the Danish Commerce and Companies Agency of the name change from Borean Pharma A/S to Roche Bio Denmark A/S; and

WHEREAS, We, Roche Bio Denmark A/S, are the owners of two U.S. applications (hereinafter "Applications") for United States Letters Patents, identified below, and of a new and useful invention as set forth in those Applications for United States Letters Patents entitled:

"Trimerising Module",

the first U.S. application filed July 17, 2000 and having U.S. Serial No. 09/445, 576, by virtue of an Assignment from the inventors of said invention to Protein Engineering Technology ApS, as recorded in the assignment records of the United States Patent & Trademark Office on June 21, 2001 at Reel No. 011939, Frame 0008; and further by virtue of the name change of Protein Engineering Technology ApS to Borean Pharma A/S as recorded in the assignment records of the United States Patent & Trademark Office on April 15, 2002 at Reel No. 012792, Frame 0272; and

the second U.S. application filed June 14, 2006 and having U.S. Serial No. 11/452,434, said second U.S. application being a continuation of said first U.S. application; and

WHEREAS,

Borean Pharma ApS
Gustav Wieds Vej 10
DK-8000 Aarhus C
Denmark;

a company also organized and existing under the laws of The United Kingdom of Denmark, desires to acquire fifty percent (50%) undivided right, title, and interest in and to said invention, the Applications, and in and to any and all improvements and/or modifications to the aforesaid

PATENT

REEL: 027780 FRAME: 0671

invention and Applications, and in and to any and all patent applications and/or Letters Patent of the United States or any other country related to the invention, the Applications, and/or related to any and all improvements and/or modifications to the aforesaid invention and Applications, including but not limited, to provisional applications, conversions to utility applications, continuations, continuations-in-part, continuing prosecution applications (CPAs), requests for continuing examination (RCEs), reissues, re-examinations, extensions, substitutes, renewals and divisions which may be filed or granted therefor, and all rights to claim priority in whole or in part on the basis of the Applications and on the basis of any and all patent applications related to the invention; and

Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, New Jersey 07110-1199
USA;

a corporation organized and existing under the laws of the State of New Jersey, also desires to acquire fifty percent (50%) undivided right, title, and interest in and to said invention, the Applications, and in and to any and all improvements and/or modifications to the aforesaid invention and Applications, and in and to any and all patent applications and/or Letters Patent of the United States or any other country related to the invention, the Applications, and/or related to any and all improvements and/or modifications to the aforesaid invention and Applications, including but not limited, to provisional applications, conversions to utility applications, continuations, continuations-in-part, continuing prosecution applications (CPAs), requests for continuing examination (RCEs), reissues, re-examinations, extensions, substitutes, renewals and divisions which may be filed or granted therefor, and all rights to claim priority in whole or in part on the basis of the Applications and on the basis of any and all patent applications related to the invention;

(Borean Pharma ApS and Hoffmann-La Roche, Inc. are collectively referred to herein as "Assignees")

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, We, Roche Bio Denmark A/S, do hereby sell, assign, transfer and set over unto

Borean Pharma ApS, its legal representatives, successors and assigns, fifty percent (50%) undivided right, title and interest, in and to said invention, the Applications and in and to any and all improvements and/or modifications to the aforesaid invention and Applications, and in and to any and all patent applications and/or Letters Patent of the United States or any other country related to said invention and Applications, and/or related to any and all improvements and/or modifications to the aforesaid invention and Applications, including but not limited to provisional applications, conversions to utility applications, continuations, continuations-in-part, continuing prosecution applications (CPAs), requests for continuing examination (RCEs), reissues, re-examinations, extensions, substitutes, renewals and divisions which may be filed or granted therefor, and all rights to claim priority in whole or in part on the basis of the Applications and on the basis of any and all patent applications related to the invention, as fully and completely as the same would have been held by us had this assignment and sale not been made. (All of the foregoing patent applications related to the invention and Applications and/or related to any and all improvements and/or modifications to the aforesaid invention and Applications are hereinafter referred to as "Other Related Patent Applications") and

Hofmann-La Roche, Inc., its legal representatives, successors and assigns, fifty percent (50%) undivided right, title and interest, in and to said invention, the Applications and in and to any and all improvements and/or modifications to the aforesaid invention and Applications, and in and to any and all patent applications and/or Letters Patent of the United States or any other country related to said invention and Applications, and/or related to any and all improvements

PATENT

REEL: 027780 FRAME: 0672

and/or modifications to the aforesaid invention and Applications, including but not limited to provisional applications, conversions to utility applications, continuations, continuations-in-part, continuing prosecution applications (CPAs), requests for continuing examination (RCEs), reissues, re-examinations, extensions, substitutes, renewals and divisions which may be filed or granted therefor, and all rights to claim priority in whole or in part on the basis of the Applications and on the basis of any and all patent applications related to the invention, as fully and completely as the same would have been held by us had this assignment and sale not been made. (All of the foregoing patent applications related to the invention and Applications and/or related to any and all improvements and/or modifications to the aforesaid invention and Applications are hereinafter referred to as "Other Related Patent Applications").

By this assignment, We, Roche Bio Denmark A/S, also do hereby sell, assign, transfer and set over unto each of said Assignees, their legal representatives, successors and assigns, fifty percent (50%) undivided right, title and interest in enforcing and asserting against any third parties, and recovering damages for past and future infringement of, any patent rights related to said Applications and said invention, and in and to any and all improvements and/or modifications to the aforesaid invention and Applications or Other Related Patent Applications.

All of the said fifty percent (50%) undivided rights, titles and interests shall vest irrevocably in said Assignees.

We, Roche Bio Denmark A/S, hereby covenant and agree, on our own behalf and on behalf of our successors and assigns, to execute any additional assignments and other documents required in connection with the prosecution of the Applications or Other Related Patent Applications as well as to perform any additional acts necessary to enable the Assignees or their successors, legal representatives and assigns, to enjoy the full rights of this Assignment, including applying for a Letters Patent for the invention in the United States of America or in any other country of the world, and assigning the Applications or any Other Related Patent Applications of any other country of the world and any Letters Patent or patents issuing thereon to the Assignees or their successors, legal representatives and assigns.

We, Roche Bio Denmark A/S, hereby agree on our own behalf and on behalf of our successors and assigns, without further compensation, to promptly at any time, upon the request of either of the Assignees, their successors and assigns, fully cooperate with each of the Assignees with respect to all matters regarding this Assignment in the United States of America or any other country, including without limitation, communicate to the Assignees or their representatives any facts known to Roche Bio Denmark A/S respecting the invention and the Applications, to execute any Other Related Patent Applications for any and all countries of the world, sign all lawful documents and make all rightful oaths and declarations relating to the invention and the Applications, execute and deliver any and all papers that may be necessary or desirable to perfect the title to the invention and the Applications, and to any Other Related Patent Applications for any and all countries of the world, in the Assignees, their successors, legal representatives or assigns, and to testify in any judicial or administrative proceeding and generally do everything possible to aid the Assignees to obtain, maintain and enforce such Letters Patent or patents, identified in this assignment, in the United States of America or any country of the world when requested so to do by either of the Assignees.

We, Roche Bio Denmark A/S, hereby authorize and request our agents, Roberts Mlotkowski & Hobbes, 7918 Jones Branch Drive, Suite 500, McLean, Virginia 22102, or an authorized employee of either of the Assignees to insert hereon any identification necessary or desirable for recordation of this document.

And We, Roche Bio Denmark A/S, request the Director of the United States Patent and Trademark Office and/or appropriate officials of any country to issue any and all Letters Patents or patents which may be granted upon said Applications, said United States application(s) or upon any Other Related Patent Applications filed in any country of the world, or upon said improvements and/or modifications or any parts thereof, which are referred to herein, jointly to the Assignees, their legal representatives, successors or assigns, as the joint owners of the entire right, title and interest in and to said Letters Patents or patents and the invention covered thereby.

ROCHE BIO DENMARK A/S

By :



Title:

Managing Director

Date:

6th December 2006